<SEC-DOCUMENT>0001387131-15-002981.txt : 20151013
<SEC-HEADER>0001387131-15-002981.hdr.sgml : 20151012
<ACCEPTANCE-DATETIME>20151013070526
ACCESSION NUMBER:		0001387131-15-002981
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151013
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151013
DATE AS OF CHANGE:		20151013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		151154550

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_101315.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center">FORM
8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-transform: uppercase; text-align: center">SECURITIES
EXCHANGE ACT OF 1934<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Date of Report (Date of earliest event
reported): October 13, 2015</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>TherapeuticsMD, Inc.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 30pt; text-align: center">(Exact Name of Registrant as Specified
in its Charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-001000</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Jurisdiction of Incorporation)</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">6800 Broken Sound Parkway NW, Third Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Boca Raton, FL 33487</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Office) (Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0; text-align: center">Registrant's telephone number, including
area code: (561) 961-1900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see</I> General Instruction A.2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>&#9;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>&#9;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>&#9;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>&#9;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(17 CFR 240.13e-4(c))</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 7.01. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulation
FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TherapeuticsMD, Inc. is
furnishing as Exhibit 99.1 to this Current Report on Form 8-K a press release on October 13, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information in this
Current Report on Form 8-K (including the exhibit) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed
to be &ldquo;filed&rdquo; for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section, nor will any of such information or exhibits be deemed incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth
by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements
and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 12%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Exhibits.</I></FONT></TD>
    <TD STYLE="width: 80%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Exhibit</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Number</U></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">TherapeuticsMD, Inc. press release dated October 13, 2015.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: -1in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;October 13, 2015</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0"><FONT STYLE="font-size: 10pt">THERAPEUTICSMD, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; padding: 0"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; padding: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ <I>Daniel A. Cartwright</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">Daniel A. Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Exhibit</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Number</U></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt"><A HREF="ex-99_1.htm">Press Release from TherapeuticsMD, Inc., dated October 13, 2015, entitled &quot;TherapeuticsMD Completes &#9;Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone &#9;Product Candidate&quot;</A></FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<BR CLEAR="ALL"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99_1.htm
<DESCRIPTION>THERAPEUTICSMD, INC. PRESS RELEASE DATED OCTOBER 13, 2015
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B><A HREF="txmd-8k_101315.htm">TherapeuticsMD 8-K</A></B></P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>



<P STYLE="font: 9pt/107% Sans-Serif; margin: 0 0 8pt 4in; text-indent: 0.5in; color: Red">&nbsp;</P>

<P STYLE="font: 9pt/107% Sans-Serif; margin: 0 0 8pt 4in; text-indent: 0.5in; color: Red"><IMG SRC="txmd_logo.jpg" ALT=""><B></B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>TherapeuticsMD Completes Enrollment
in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><I>&ndash; Study evaluates TX-001HR,
first bio-identical combination product candidate to treat vasomotor symptoms of menopause &ndash;</I></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>BOCA RATON, Fla., October 13, 2015</B>
&ndash; TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women&rsquo;s healthcare company, today announced that the company
has completed patient enrollment in the Replenish Trial, a phase 3 clinical trial evaluating multiple doses of the investigational
once-daily oral softgel capsule, TX-001HR (estradiol and progesterone), to reduce the frequency and severity of moderate to severe
vasomotor symptoms (VMS), including hot flashes and night sweats, in postmenopausal women.</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD believes TX-001HR, if
approved by the FDA, would represent the first time estradiol and progesterone (bio-identical to the estradiol and progesterone
produced by a woman&rsquo;s ovaries), would be approved for use in a single, combined product. Patented TX-001HR was developed
with SYMBODA&trade;, an advanced technology for solubilizing the bio-identical hormones 17&beta;-estradiol and progesterone.</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&quot;There are currently no FDA-approved
oral bio-identical estradiol and progesterone combination products for women experiencing hot flashes and night sweats. Approximately
1 million to 2.5 million women are currently estimated to use non FDA-approved compounded menopausal hormone therapy in the U.S.
TherapeuticsMD seeks to address the unmet needs of post-menopausal women as we develop potentially the first FDA-approved 17&beta;-estradiol
plus progesterone combination softgel capsule in the United States,&quot; stated Robert G. Finizio, Chief Executive Officer of
TherapeuticsMD. &quot;Completion of patient recruitment in the Replenish Trial marks an important milestone in our development
efforts and illustrates continued progress towards our goal of bringing novel hormone therapy options to women.&quot;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Trial Design</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A pivotal safety and efficacy study,
the Replenish Trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating
four doses of TX-001HR: combined estradiol 1 mg/progesterone 100 mg; combined estradiol 0.5 mg/progesterone 100 mg; combined estradiol
0.5 mg/progesterone 50 mg; and combined estradiol 0.25 mg/progesterone 50 mg. If approved, each of these combinations of estradiol
and progesterone doses would represent a lower daily dose of estradiol and/or progesterone than those in currently approved products.
The 12-month trial enrolled more than 1,750 healthy postmenopausal women (age 40 to 65 years old) in approximately 110 sites across
the United States. The primary efficacy objective is to determine whether TX-001HR given daily is effective at reducing the frequency
and severity of moderate to severe vasomotor symptoms associated with menopause when compared to placebo treatment at weeks 4 and
12. The Replenish Trial will also evaluate whether ongoing treatment with TX-001HR given daily is effective at achieving a &le;1%
incidence rate of endometrial hyperplasia following 12 months of therapy (primary safety objective).</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>About SYMBODA Technology</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">SYMBODA, meaning &quot;similar to the
body,&quot;&nbsp;is a technology for formulation of solubilized hormones identical in chemical structure (bio-identical) to the
estradiol and progesterone women naturally produce. TherapeuticsMD is leveraging this leading-edge technology to create new bio-identical
drug forms and combinations that are designed to meet FDA uniformity and stability requirements.</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Hormone Therapy (also referred
to as Hormone Replacement Therapy or Menopausal Hormone Therapy)</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Hormone Therapy (HT) is the administration
of hormones to treat menopausal symptoms that arise from a reduction of naturally occurring hormones. Current HT options include
FDA-approved combination products using non-bio-identical hormones, FDA-approved estrogen-only and progestogen-only products and
non-FDA approved compounded bioidentical products. According to Symphony Health Solutions, the current market for FDA-approved
combination HT products is approximately $661 million annually, while various sources estimate that pharmacy-compounded, bioidentical
HT product sales are approximately $1.5 billion annually.</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>About TherapeuticsMD, Inc. </B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD, Inc. is an innovative
healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA&trade; technology,
TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through
a variety of dosage forms and administration routes. The company&rsquo;s clinical development pipeline includes two phase 3 products.
The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins
under the vitaMedMD<SUP>&reg;</SUP> and BocaGreenMD<SUP>&reg;</SUP> brands. More information is available at the following websites:
www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com and www.bocagreenmd.com.</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release by TherapeuticsMD,
Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating
to TherapeuticsMD&rsquo;s objectives, plans and strategies as well as statements, other than historical facts, that address activities,
events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These
statements are often characterized by terminology such as &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;should,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;projects,&rdquo; &ldquo;positioned,&rdquo; &ldquo;strategy&rdquo; and similar expressions and are based on assumptions and
assessments made in light of management&rsquo;s experience and perception of historical trends, current conditions, expected future
developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the
date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of
new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject
to risks and uncertainties, many of which are outside of the company&rsquo;s control. Important factors that could cause actual
results, developments and business decisions to differ materially from forward-looking statements are described in the sections
titled &ldquo;Risk Factors&rdquo; in the company&rsquo;s filings with the Securities and Exchange Commission, including its most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following:
the company&rsquo;s ability to maintain or increase sales of its products; the company&rsquo;s ability to develop and commercialize
its hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results
of the company&rsquo;s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval
of the company&rsquo;s hormone therapy drug candidates; the company&rsquo;s reliance on third parties to conduct its clinical trials,
research and development and manufacturing; the availability of reimbursement from government authorities and health insurance
companies for the company&rsquo;s products; the impact of product liability lawsuits; the influence of extensive and costly government
regulation; the volatility of the trading price of the company&rsquo;s common stock and the concentration of power in its stock
ownership. PDF copies of the company&rsquo;s historical press releases and financial tables can be viewed and downloaded at its
website: www.therapeuticsmd.com/pressreleases.aspx.</I></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"># # #</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">Contact:</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">Dan Cartwright</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">Chief Financial Officer</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">561-961-1900</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">Dan.Cartwright@TherapeuticsMD.com</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>txmd_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd_logo.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  A 0X# 2(  A$! Q$!_\0
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M*0?L-_LY>)O!'PT;XU?$#4?!G@KX=Z<='T_39/$ LH=814A2,.I!>1XUCZQ
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MS%VA1&  *[7QE\-?VG_V/[";Q'X<^($?QJ\/Z>OG7VAZS8^5J#Q#ES"X+,S
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M)7&.,5['^S'^Q=\+OV-?#D^E_#3P7I'A6WO"#=2VZM)<W>.GFSR%I7QS@,Q
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M_%#PGX,C\3CQKXE\6:G#IJ6/A0+JTEB)#@33>42 H)7Y%+2'.0A -=W^U/\
M\$]/@U^VI]GD^)7@+2/$5[:+Y<%_F2UOHDZ[!/"R2%/]DL5Y/%97[+O_  3!
M^!/[&GB%]9^'OP\TG1];9&C&ISRS7UY$K<,L<L[NT8(X.PC/>MJ^)P->;Q%2
M,N9[I6M?O?>W6UC##X7,,/".&IRBX1T4G?FY>UMF^E[KT.._:G_;7_9@\0_&
M^]^ /QEO?#+Z@+."_>W\36*C2]\N3&BW$@V).%(8'*\.,-G('YT?\%)/@/\
M!?\ 8(^*7PU\<_LG>._[)^*VK>(H+.+POX>US^U;>^MY"02RAW94,@2,QNQ6
M02$!>":_7/\ :4_8J^%7[8.D16?Q)\#:%XK6V4I!/<PE+JV!ZB.="LJ#GHK
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MZKJSW?\ 27R1]/E&5T<NP<,'0NXQZO5MMW;?FVVWYL****P/2"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
